Compare NOK & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NOK | ILMN |
|---|---|---|
| Founded | 1865 | 1998 |
| Country | Finland | United States |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.3B | 18.9B |
| IPO Year | N/A | 2000 |
| Metric | NOK | ILMN |
|---|---|---|
| Price | $6.22 | $129.59 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 15 |
| Target Price | $7.50 | ★ $117.27 |
| AVG Volume (30 Days) | ★ 28.2M | 1.7M |
| Earning Date | 01-29-2026 | 02-05-2026 |
| Dividend Yield | ★ 1.67% | N/A |
| EPS Growth | ★ 129.18 | N/A |
| EPS | 0.20 | ★ 4.46 |
| Revenue | ★ $23,170,245,221.00 | $4,288,000,000.00 |
| Revenue This Year | $6.46 | N/A |
| Revenue Next Year | $3.89 | $2.08 |
| P/E Ratio | $31.11 | ★ $29.49 |
| Revenue Growth | ★ 5.88 | N/A |
| 52 Week Low | $4.00 | $68.70 |
| 52 Week High | $8.19 | $153.06 |
| Indicator | NOK | ILMN |
|---|---|---|
| Relative Strength Index (RSI) | 49.32 | 56.87 |
| Support Level | $6.17 | $126.44 |
| Resistance Level | $6.29 | $137.09 |
| Average True Range (ATR) | 0.11 | 3.66 |
| MACD | 0.00 | -0.62 |
| Stochastic Oscillator | 38.00 | 42.96 |
Nokia provides telecom equipment and services that are used to build wireless and fixed-line networks. It operates in four segments. The mobile networks segment sells equipment and services to telecom carriers to power public wireless networks. Network infrastructure focuses on fixed-line networks, including switching and routing equipment, optical components, and devices used in fiber-to-the-premises networks. The cloud and network services segment develops software used to operate the core of carrier wireless networks and build private networks for enterprises. Nokia also has a sizable research and patent business, where it licenses technology used by handset providers, consumer electronics firms, and other firms making electronic and Internet of Things products.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.